Co-infections In COVID-19 Patients Research Articles

Respiratory bacterial pathogen spectrum among COVID-19 infected and non–COVID-19 virus infected pneumonia patients

COVID-19 positive (194) and negative (212) pneumonia patients were selected to analyze bacterial pathogens coinfection. Results showed that 50% of COVID-19 patients were coinfected or carried bacterial pathogens. Bordetella pertussis infection rate was significantly higher in positive patients. Consequently, preventions should be taken to control bacterial pathogens coinfection in COVID-19 patients.

Systemic mycoses: a potential alert for complications in COVID-19 patients.

As the global COVID-19 pandemic spreads worldwide, new challenges arise in the clinical landscape. The need for reliable diagnostic methods, treatments and vaccines for COVID-19 is the major worldwide urgency. While these goals are especially important, the growing risk of co-infections is a major threat not only to the health systems but also to patients' lives. Although there is still not enough published statistical data, co-infections in COVID-19 patients found that a significant number of patients hospitalized with COVID-19 developed secondary systemic mycoses that led to serious complications and even death. This review will discuss some of these important findings with the major aim to warn the population about the high risk of concomitant systemic mycoses in individuals weakened by COVID-19.

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.

We observed bacterial or fungal coinfections in COVID-19 patients admitted between March 1 and April 18, 2020 (152 of 4,267, 3.6%). Among these patients, mortality was 57%; 74% were intubated; 51% with bacteremia had central venous catheters. Time to culture positivity was 6-7 days, and 79% had received prior antibiotics. Metallo-β-lactamase-producing E. cloacae coinfections occurred in 5 patients.

Fungal co-infection in COVID-19 patients: Should we be concerned?

Critically ill COVID-19 patients have higher pro-inflammatory (IL-1, IL-2, IL-6, tumor necrosis alpha) and anti-inflammatory (IL-4, IL-10) cytokine levels, less CD4 interferon-gamma expression, and fewer CD4 and CD8 cells. This severe clinical situation increases the risk of serious fungal infections, such as invasive pulmonary aspergillosis, invasive candidiasis or Pneumocystis jirovecii pneumonia. However, few studies have investigated fungal coinfections in this population. We describe an update on published reports on fungal coinfections and our personal experience in three Spanish hospitals. We can conclude that despite the serious disease caused by SARS-CoV-2 in many patients, the scarcity of invasive mycoses is probably due to the few bronchoscopies and necropsies performed in these patients because of the high risk in aerosol generation. However, the presence of fungal markers in clinically relevant specimens, with the exception of bronchopulmonary colonization by Candida, should make it advisable to early implement antifungal therapy.

Co-infections in COVID-19 patients and the importance of microbial diagnosis for disease management

Co-infections in COVID-19 patients and the importance of microbial diagnosis for disease managementR. Khalilov1,2,3, A. Eftekhari 2,4, H. Hosainzadegan2,4*1 Department of Biophysics and Biochemistry, Baku State University, 23 academician Z.Khalilov Str., Baku AZ1148, Azerbaijan2Joint

Co-infections in COVID-19 patients and the importance of microbial diagnosis for disease management

Co-infections in COVID-19 patients and the importance of microbial diagnosis for disease management

Co-infections in COVID-19 patients and the importance of microbial diagnosis for disease management

Co-infections in COVID-19 patients and the importance of microbial diagnosis for disease management